Login to Your Account

Walking the Double Bottom-Line

PaxVax Preps Cholera Vaccine For Phase III; H5N1 for Phase II

By Trista Morrison
Staff Writer

Tuesday, March 20, 2012
PaxVax Corp. is gearing up for Phase III trials with PXVX-0200, a fast-acting cholera vaccine designed to target both developing countries and the more lucrative travelers' market – exemplifying PaxVax's "double bottom-line" mission, according to the firm's executive vice president and chief operating officer, Nima Farzan.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription